The World's Greatest Investing Community
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Exciting pipeline-- DRN5500 fastracked, successful phase2a trial-- for treatmentment of neurpathy-- potential blackbuster. Also, DB959 will be out-licensed should bring in some good revenue. On top of that DARA has marketing rights to Soltamox for treatment of breast cancer, and has already launched Bionect for burns associated with radiation therapy. Absurdly cheap on valuation basis-- could see $2.00 in no time. Long-term much higher Worth a caps pick.